Trevogrumab (Anti-Myostatin) Can Help Preserve Lean Mass During and After Semaglutide-Induced Weight Loss
Regeneron said the 75-milligram dose preserved over 70% of muscle loss at 52 weeks, while it dropped 6.7% with semaglutide alone.
6 Articles
6 Articles
Regeneron's Trevogrumab With Novo's Semaglutide Halves Muscle Loss in Obesity Trial, Data Show
An experimental weight-loss drug being developed by Regeneron used in combination with Novo Nordisk's semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide alone in a study of patients with obesity, according to data being presented at a medical meeting.With the explosive popularity of GLP-1 weight-loss drugs such as Novo's semaglutide, sold as Wegovy for obesity, there has been growing concern about si…
Regeneron weight-loss drug halves muscle loss in combination with Novo’s semaglutide in trial - Regional Media News
By Sriparna Roy Sept 30 (Reuters) - An experimental weight-loss drug being developed by Regeneron used in combination with Novo Nordisk's semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide alone in a study of patients with obesity, [...]
Regeneron drug halves muscle loss in combination with Novo’s semaglutide in trial
By Sriparna Roy Sept 30 (Reuters) - An experimental weight-loss drug being developed by Regeneron used in combination with Novo Nordisk's semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide alone in a study o...
Trevogrumab (anti-myostatin) can help preserve lean mass during and after semaglutide-induced weight loss
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and in press at The Lancet shows that trevogrumab, which inhibits a protein that negatively regulates muscle mass, can reduce lean mass loss during semaglutide treatment by 50% compared with semaglutide and placebo.
Nairabrocal Endocrinology In Phase II One of the concerns that arouses treatment with GLP-1 receptor agonists is its possible impact on body composition.The results of a Phase II clinical trial by the pharmaceutical company Regeneron show that inhibition of myostatin with trevogrumab can reduce by about half the loss of lean mass associated with treatment with semaglutide.The study is presented at the Annual Meeting of the European Diabetes Stud…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
